Ignyta Inc. (RXDX)

Trade RXDX now with
3/16/2016 7:08:23 AM Ignyta Issues Inducement Award To One New Non-executive Employee
3/10/2016 7:08:24 AM Ignyta Reports Initiation Of Phase 1b Basket Trial Of RXDX-105
1/11/2016 7:17:12 AM Ignyta Unveils Aspirational “5x5” Goal And Announces Strategic Priorities For 2016
12/9/2015 7:04:28 AM Ignyta Announces Initiation Of STARTRK 'Next Generation' Phase 1/1b Pediatric Clinical Trial Of Entrectinib
12/8/2015 7:09:26 AM Ignyta Gets Orphan Drug Designation In European Union For Entrectinib For Treatment Of Neuroblastoma
11/30/2015 7:13:25 AM Entrectinib Selected As First Investigational Cancer Agent Included In EORTC SPECTA Precision Medicine Trial Program
11/9/2015 7:38:21 AM Ignyta Q3 Loss/shr $0.49 Vs. Loss/shr $0.55 Prior Year
11/8/2015 3:10:34 PM Ignyta Announces Acquisition Of Exclusive Rights To Taladegib Oncology Program From Lilly
11/8/2015 12:49:48 PM Ignyta Announces Interim Data From RXDX-105 Phase 1 Clinical Trial
9/30/2015 7:06:29 AM Ignyta Says Begins STARTRK-2 Phase 2 Clinical Trial Of Entrectinib
9/27/2015 12:10:45 PM Ignyta Announces Updated Interim Data From Entrectinib Phase 1 Clinical Trials At The 2015 European Cancer Congress
8/10/2015 4:27:38 PM Ignyta Posts Q2 Loss/share Of $0.51 Vs. Loss $0.28 Year Ago
7/29/2015 7:12:05 AM Ignyta Says US FDA Clears IND Application For Its New Chemical Entity RXDX-107
6/10/2015 9:53:59 PM Ignyta Announces Pricing Of Offering Of 4.285 Mln Shares At $17.50/shr
6/9/2015 4:13:46 PM Ignyta Announces Proposed Public Offering Of $75 Mln Of Common Stock